Alterity Therapeutics Presents Detailed Phase 2 Data Supporting ATH434 Advancement to Phase 3 for MSA

summarizeSummary

Alterity Therapeutics announced detailed positive Phase 2 data for its lead MSA drug candidate, ATH434, at recent medical conferences, reinforcing its path to Phase 3.

check_boxKey Events

• Positive Phase 2 Data Presented

  Detailed clinical, biomarker, and imaging data for ATH434 in Multiple System Atrophy (MSA) was presented at three medical conferences, including ISMRM, MDSANZ, and the MSA Symposium.

• Significant Slowing of Disease Progression

  The Phase 2 trial demonstrated statistically significant slowing of disease progression and reduced iron accumulation, supporting ATH434's potential as a disease-modifying treatment for MSA.

• Advancing to Phase 3

  The presented data directly informs the design of the upcoming Phase 3 trial, with an End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm the development path.

• Novel Biomarker Approach

  New research highlights the use of Quantitative Susceptibility Mapping (QSM) to detect progressive iron accumulation and CSF NfL as a prognostic covariate, enhancing trial design and patient monitoring.

auto_awesomeAnalysis

Alterity Therapeutics presented detailed positive Phase 2 clinical, biomarker, and imaging data for its lead candidate ATH434 in Multiple System Atrophy (MSA) at three medical conferences. The data reinforces ATH434's potential as a disease-modifying treatment, showing statistically significant slowing of disease progression and reduced iron accumulation. This strong evidence directly informs the design of the upcoming Phase 3 trial, with an End-of-Phase 2 FDA meeting expected mid-2026 to confirm the path forward.